Cerevel Therapeutics Holdings, Inc.
CERE
Hisse Senetlerindeki Sıralama
#2813
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm... Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing treatments for a range of neuroscience disorders. The company boasts a robust pipeline of therapeutic candidates currently undergoing various phases of clinical evaluation. Key assets include emraclidine, a positive allosteric modulator (PAM) in Phase 1b trials for schizophrenia. Another PAM, Darigabat, is being assessed in a Phase 2 proof-of-concept study for drug-resistant focal onset seizures in epilepsy, as well as in a Phase 1 trial for acute anxiety. For Parkinson's disease, Cerevel is advancing Tavapadon, a selective dopamine D1/D5 partial agonist, through Phase 3 clinical trials for both early and late stages of the condition. A related compound, CVL-871, also a selective dopamine D1/D5 partial agonist, is in Phase 2a trials for dementia-related apathy. The company's portfolio further includes CVL-936, a selective dopamine D3-preferring antagonist in Phase I for substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist targeting major depressive disorder and substance use disorder; and CVL-047, a selective PDE4 inhibitor also aimed at major depressive disorder and substance use disorder. Beyond individual compounds, Cerevel is actively developing an M4 agonist program for psychosis and related indications, alongside an LRRK2 inhibitor program designed to address the progression of Parkinson's disease. Founded in 2018, Cerevel Therapeutics is headquartered in Cambridge, Massachusetts.
Hisse Fiyatı
$44.96
Son senkronizasyon: 2024-08-01
Piyasa Değeri
$6.67B
Değişim (1 gün)
0.00%
Değişim (1 yıl)
0.00%
Ülke
US
Ticaret Cerevel Therapeutics Holdings, Inc. (CERE)
Kategori
Healthcare
Cerevel Therapeutics Holdings, Inc. (CERE) için tedavüldeki hisse sayısı
March 2024 itibarıyla tedavüldeki hisse sayısı: 181.61M
Cerevel Therapeutics Holdings, Inc. şirketinin son finansal raporlarına ve hisse fiyatına göre, mevcut tedavüldeki hisse sayısı 181.61M'dir. December 2022 sonunda şirketin 151.27M tedavüldeki hissesi vardı. Tedavüldeki hisse sayısı genellikle hisse bölünmeleri ve hisse geri alımları ile etkilenir.
Cerevel Therapeutics Holdings, Inc. (CERE) için 2012 - 2026 tarihleri arasındaki hisse geçmişi
Her yıl sonunda tedavüldeki hisse sayısı
| Yıl | Tedavüldeki Hisse Sayısı | Değiştir |
|---|---|---|
| 2026 (TTM) | 181.61M | 12.07% |
| 2023 | 162.06M | 7.13% |
| 2022 | 151.27M | 10.76% |
| 2021 | 136.58M | 15.57% |
| 2020 | 118.18M | -7.04% |
| 2019 | 127.12M | 79.86% |
| 2018 | 70.68M | 396.40% |
| 2015 | 14.24M | 0.00% |
| 2014 | 14.24M | 0.00% |
| 2013 | 14.24M | 0.00% |
| 2012 | 14.24M | 0.00% |
Benzer şirketler veya rakipler için tedavüldeki hisse sayısı
| Şirket | Tedavüldeki Hisse Sayısı | Fark | Ülke |
|---|---|---|---|
| 253.90M | 39.80% |
US
|
|
| 396.00M | 118.05% |
US
|
|
| 478.91M | 163.70% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -65.76% |
NL
|
